Ten63 Therapeutics
Durham, US · Founded 2019 · Delaware corporation · 33 employees on LinkedIn · 10 known investors
Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets. It runs an internal pipeline of first-in-class and best-in-class programs across oncology and other serious diseases.
Founders & leadership
Ten63 Therapeutics was founded in 2019 by Mark A. Hallen.
MA
Mark A. HallenFounder
MF
Marcel FrenkelNamed on SEC filing
DP
Damien PettyNamed on SEC filing
JW
Jia Wei XuNamed on SEC filing
Investors · 10
Cape Fear BioCapitalDurham
DFJ DragonFundShanghai
Draper AssociatesSan Mateo · $500K – $5M
Duke Capital PartnersDurham
AlexandriareportedPasadena
HatterasreportedRaleigh
Hatteras Venture Partnersreported · 2 sourcesResearch Triangle · $500K – $4M
Morpheus VenturesreportedSherman Oaks · $1M – $10M
SOSVreportedNew York · $30K – $550K
Also in the syndicate · 1
the Sigma Group
Funding
SEC filings, press & company announcements$18M disclosed across 2 of 3 rounds · 2021–2026
- $15.9MSeries AMay 2023 · 2 sources
Hatteras Venture Partners (lead), Alexandria Venture Investments, Draper Associates, Morpheus Ventures, SOSV, the Sigma Group
Source ↗
▶$2.1MraisedJan 2021 · 7 investors · OtherRule 506(b)
▶$2.1MraisedJan 2021 · 7 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- Marcel FrenkelExecutive Officer, Director
- Mark A. HallenExecutive Officer, Director
- Damien PettyDirector
- Jia Wei XuDirector
- Offering amount
- $2.1M
- Amount sold
- $2.1M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2019
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 6
by search overlapTenax Therapeutics5 shared keywordsTenax Therapeutics is a clinical-stage pharmaceutical company developing TNX-103, an oral formulation of the drug levosimendan, to treat pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF). The company focuses on this cardiovascular and pulmonary disease, which currently has no approved treatments.
Tensixty5 shared keywordsTenSixty uses machine learning and cell biology expertise to identify novel antibody targets on cancer cells for the development of new cancer therapeutics. The company combines AI with high-throughput technologies to discover improved drug candidates for oncology.
Dialectic Therapeutics4 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Tenaya Therapeutics4 shared keywordsTenaya Therapeutics is a clinical-stage biotechnology company developing gene therapies for inherited heart diseases, including TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-associated arrhythmogenic right ventricular cardiomyopathy. It focuses on curative treatments addressing the genetic causes of cardiomyopathies for patients with heart disease.
Tenvie3 shared keywordsTenvie is a clinical-stage biopharmaceutical company developing small molecule and biologic therapeutics for neurological and peripheral diseases. The company is led by a team with expertise in biotech and precision medicine, targeting treatments for patients and caregivers affected by neurological conditions.
Dianthus Therapeutics3 shared keywordsDianthus Therapeutics develops antibody-based therapies for patients with severe autoimmune diseases, including its lead complement C1s inhibitor claseprubart (DNTH103) and a bifunctional inhibitor DNTH212 designed for self-administered subcutaneous injection. The company operates in the biotech and drug development sector.
Companies competing with Ten63 Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Ten63 Therapeutics do?
- Ten63 develops drug-discovery technology that combines generative chemistry with quantum-accurate molecular simulation, including BEYOND (a large quantum chemistry model) and Sentinel (a virtual CSO for target selection), to design therapeutics against previously undruggable targets. It runs an internal pipeline of first-in-class and best-in-class programs across oncology and other serious diseases.
- Who founded Ten63 Therapeutics?
- Ten63 Therapeutics was founded by Mark A. Hallen in 2019.
- Who are Ten63 Therapeutics's investors?
- Ten63 Therapeutics's investors include Cape Fear BioCapital, DFJ DragonFund, Draper Associates, Duke Capital Partners, Alexandria, Hatteras, Hatteras Venture Partners, Morpheus Ventures and 1 more.
- How much funding has Ten63 Therapeutics raised?
- Ten63 Therapeutics has disclosed $18M raised across 2 of its 3 known rounds.
- Where is Ten63 Therapeutics headquartered?
- Ten63 Therapeutics is headquartered in Durham, US.